4 recruiting, 3 completed, 1 terminated, 1 withdrawn. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 4, Completed 3, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Terminated 1 |
Follow Blood Cancer: new trials by email Literature Review of Blood Cancer trials Research Report on Blood Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers IDP-023, Rituximab, Daratumumab - NHL, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Indapta Therapeutics, INC. | 128 | 2023-10-25 | 2025-06-03 |
| Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies KCAT19 T cells - Blood Cancer | Phase 1 | Recruiting | University College, London | 12 | 2023-02-06 | 2026-08-11 |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Ivosidenib, Enasidenib, Fedratinib - IDH Mutation, IDH1 Mutation | Phase 1 | Withdrawn | University of Chicago | 2021-10-29 | 2024-07-31 | |
| A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer TL-895 - COVID-19, Sars-CoV2 | Phase 1 | Completed | Telios Pharma, Inc. | 7 | 2020-07-09 | 2021-05-12 |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL MT-3724 Phase 1, MT-3724 Phase 2 - Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Terminated | Molecular Templates, Inc. | 38 | 2015-02-01 | 2022-08-18 |
| A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies MEDI-551 - Blood Cancer, Advanced B Cell Malignancies | Phase 1 | Completed | AstraZeneca | 32 | 2011-05-25 | 2017-06-12 |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) Darbepoetin alfa - Blood Cancer, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Peter L Greenberg | 21 | 2002-02-01 | 2013-02-04 |
Hematologic Neoplasms (9) · Leukemia (4) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · COVID-19 (1) · Carcinoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Neoplasms by Site (9) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Bone Marrow Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2)
Cyclophosphamide (2) · aldesleukin (2) · Azacitidine (1) · Darbepoetin alfa (1) · Interleukin-2 (1) · Mesna (1) · Rituximab (1) · daratumumab (1) · enasidenib (1) · fedratinib (1) · fludarabine (1) · fludarabine phosphate (1) · inebilizumab (1) · isatuximab (1) · ivosidenib (1)
AstraZeneca (1) · Indapta Therapeutics, INC. (1) · Jacqueline Garcia, MD (1) · Molecular Templates, Inc. (1) · National Cancer Institute (NCI) (1) · Peter L Greenberg (1) · Telios Pharma, Inc. (1) · University College, London (1) · University of Chicago (1)
United States (7) · Belarus (1) · Canada (1) · Georgia (1) · Israel (1) · Japan (1) · Moldova (1) · Poland (1) · Serbia (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Jacqueline Garcia, MD (1) · James N Kochenderfer, M.D. (1) · Olatoyosi Odenike, MD (1) · Peter L Greenberg (1)